نتایج جستجو برای: containing vaginal gel

تعداد نتایج: 467619  

Journal: :PLoS ONE 2008
Vera Halpern Folasade Ogunsola Orikomaba Obunge Chin-Hua Wang Nneka Onyejepu Oyinola Oduyebo Doug Taylor Linda McNeil Neha Mehta John Umo-Otong Sakiru Otusanya Tania Crucitti Said Abdellati

BACKGROUND This trial evaluated the safety and effectiveness of 6% cellulose sulfate vaginal gel in preventing male-to-female vaginal transmission of HIV, gonorrhea and chlamydial infection. METHODS This Phase III, double-blind, randomized, placebo-controlled trial was conducted between November 2004 and March 2007 in Lagos and Port Harcourt, Nigeria. We enrolled 1644 HIV-antibody negative wo...

2015
Florence van Hunsel Sonja van de Koppel Eugène van Puijenbroek

Two 54-year-old women developed abdominal cramps and vaginal hemorrhage as a result of endometrial hyperplasia during treatment with a hop-containing phytotherapeutic product (MenoCool®) for post-menopausal complaints. The women used the hop-containing phytotherapeutic product (418 mg of hop per tablet) twice daily (1 and 0.5 tablets by both patient A and B). Patient A developed abdominal cramp...

Journal: :Asian Journal of Pharmaceutical and Clinical Research 2017

Journal: :Translational medicine communications 2021

Abstract Background Strict adherence to antiretroviral-based microbicide use is important for effective HIV prevention. We previously developed a composite measure of product adherence, protocol compliance, and semen exposure determining vaginal tenofovir (TFV) 1% gel applicators through biomarkers residual drug analyses. In this study, we tested the ability in vaginally used TFV from Phase III...

2013
Craig W. Hendrix Beatrice A. Chen Vijayanand Guddera Craig Hoesley Jessica Justman Clemensia Nakabiito Robert Salata Lydia Soto-Torres Karen Patterson Alexandra M. Minnis Sharavi Gandham Kailazarid Gomez Barbra A. Richardson Namandje N. Bumpus

BACKGROUND Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in men and women prompting assessment of variation in drug concentration as an explanation. Knowledge of tenofovir concentration and its active form, tenofovir diphosphate, at the putative vaginal and rectal site of action ...

Journal: :PLoS ONE 2008
Stuart G. Turville Meropi Aravantinou Todd Miller Jessica Kenney Aaron Teitelbaum Lieyu Hu Anne Chudolij Tom M. Zydowsky Michael Piatak Julian W. Bess Jeffrey D. Lifson James Blanchard Agegnehu Gettie Melissa Robbiani

Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident with demonstrating efficacy in vivo, is central to advancing new generation microbicides. We evaluated Carraguard and a new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (PC-817). Since dendritic cells...

Journal: :Lancet 2011
Marta Jozwiak Katrien Oude Rengerink Marjan Benthem Erik van Beek Marja G K Dijksterhuis Irene M de Graaf Marloes E van Huizen Martijn A Oudijk Dimitri N M Papatsonis Denise A M Perquin Martina Porath Joris A M van der Post Robbert J P Rijnders Hubertina C J Scheepers Marc E A Spaanderman Maria G van Pampus Jan Willem de Leeuw Ben W J Mol Kitty W M Bloemenkamp

BACKGROUND Induction of labour is a common obstetric procedure. Both mechanical (eg, Foley catheters) and pharmacological methods (eg, prostaglandins) are used for induction of labour in women with an unfavourable cervix. We aimed to compare the effectiveness and safety of induction of labour with a Foley catheter with induction with vaginal prostaglandin E2 gel. METHODS We did an open-label,...

2013
Yajing Gao David F. Katz

BACKGROUND Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting results. Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens. Topical Tenofovir delivery to the vaginal environment is compl...

2011
Sara J. Whitehead Catherine McLean Supaporn Chaikummao Sarah Braunstein Wat Utaivoravit Janneke H. van de Wijgert Philip A. Mock Taweesap Siraprapasiri Barbara A. Friedland Peter H. Kilmarx Lauri E. Markowitz

BACKGROUND Few studies of microbicide acceptability among HIV-infected women have been done. We assessed Carraguard® vaginal gel acceptability among participants in a randomized, controlled, crossover safety trial in HIV-infected women in Thailand. METHODOLOGY/PRINCIPAL FINDINGS Participants used each of 3 treatments (Carraguard gel, methylcellulose placebo gel, and no product) for 7 days, we...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید